DNA plasmid HIV vaccine design, number of doses, participant gender, and body mass index affect T-cell responses across HIV vaccine clinical trials

C Morgan; X Jin; X Yu; S De Rosa; J Kublin; B Metch; M Keefer; H NIAID

首页> 外文期刊>Retrovirology >DNA plasmid HIV vaccine design, number of doses, participant gender, and body mass index affect T-cell responses across HIV vaccine clinical trials

【24h】

DNA plasmid HIV vaccine design, number of doses, participant gender, and body mass index affect T-cell responses across HIV vaccine clinical trials

机译：DNA质粒HIV疫苗的设计，剂量数量，受试者的性别和体重指数会影响整个HIV疫苗临床试验中的T细胞反应

获取原文

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《Retrovirology》 |2012年第s2期|共页
作者
C Morgan; X Jin; X Yu; S De Rosa; J Kublin; B Metch; M Keefer; H NIAID;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种
中图分类细胞生物化学;
关键词

相似文献

外文文献
中文文献
专利

1. Lessons from IAVI-006, a Phase I clinical trial to evaluate the safety and immunogenicity of the pTHr.HIVA DNA and MVA.HIVA vaccines in a prime-boost strategy to induce HIV-1 specific T-cell responses in healthy volunteers [J] . Guimaraes-Walker A., Mackie N., McCormack S., Vaccine . 2008,第51期

机译：IAVI-006的经验教训，I期临床试验旨在评估pTHr.HIVA DNA和MVA.HIVA疫苗在健康志愿者中诱导HIV-1特异性T细胞应答的初免-加强策略的安全性和免疫原性
2. DNA Priming Increases Frequency of T-Cell Responses to a Vesicular Stomatitis Virus HIV Vaccine with Specific Enhancement of CD8+ T-Cell Responses by Interleukin-12 Plasmid DNA [J] . Shuying S. Li, Nidhi K. Kochar, Marnie Elizaga, Clinical and vaccine immunology: CVI . 2017,第11期

机译：DNA启动增加白介素12质粒DNA对水泡性口腔炎病毒HIV疫苗的T细胞应答的频率，并特异性增强CD8 + T细胞应答。
3. Multiple factors affect immunogenicity of DNA plasmid HIV vaccines in human clinical trials [J] . Jin Xia, Morgan Cecilia, Yu Xuesong, Vaccine . 2015,第20期

机译：多种因素影响人类临床试验中DNA质粒HIV疫苗的免疫原性
4. HIV Epidemic Profile in Russia and Preparing for Clinical Trials of the First Russian HIV Vaccine "VICHREPOL" [C] . Nikolaeva, S. Korobova, A. Chevalier International AIDS Conference . 2004

机译：俄罗斯艾滋病流行性概况，并为第一个俄罗斯艾滋病毒疫苗“vichrepol”的临床试验
5. Evaluation of different SIV plasmid DNA vaccines: A model for HIV vaccine development. [D] . Busch, Marc Gregory. 2004

机译：不同SIV质粒DNA疫苗的评估：HIV疫苗开发的模型。
6. DNA plasmid HIV vaccine design number of doses participant gender and body mass index affect T-cell responses across HIV vaccine clinical trials [O] . C Morgan, X Jin, X Yu, 2012

机译：DNA质粒HIV疫苗的设计剂量数量受试者的性别和体重指数会影响整个HIV疫苗临床试验中的T细胞反应
7. DNA plasmid HIV vaccine design, number of doses, participant gender, and body mass index affect T-cell responses across HIV vaccine clinical trials [O] . C Morgan, X Jin, X Yu, 2012

机译：DNA质粒HIV疫苗的设计，剂量数量，受试者的性别和体重指数会影响整个HIV疫苗临床试验中的T细胞反应
8. Vaxfectin (registered trademark) Enhances Both Antibody and In Vitro T Cell Responses to Each Component of a 5-gene Plasmodium falciparum Plasmid DNA Vaccine Mixture Administered at Low Doses [R] . Sedegah, M., Rogers, W. O., Belmonte, M., 2010

机译：Vaxfectin（注册商标）增强抗体和体外T细胞对5基因恶性疟原虫质粒DNa疫苗混合物各组分的低剂量反应

DNA plasmid HIV vaccine design, number of doses, participant gender, and body mass index affect T-cell responses across HIV vaccine clinical trials

著录项

相似文献

相关主题

期刊订阅